STAT+: Psychedelics companies see FDA panel’s vote as a growth opportunity, not a roadblock

STAT June 6, 2024
Meghana Keshavan

A day after a panel of advisers to the Food and Drug Administration expressed deep concerns about the use of MDMA to help treat post-traumatic stress disorder, companies working to develop other psychedelics said their optimism had not been dimmed — and that the concerns provided a clearer blueprint for what it might take to get such a drug approved.

The advisory committee overwhelmingly voted that Lykos Therapeutics, which is seeking FDA approval for MDMA and therapist oversight,...

Today's Sponsors

Today's Sponsor